- Conditions
- Lymphoma
- Interventions
- Bleomycin Sulfate, Doxorubicin Hydrochloride, Procarbazine Hydrochloride, Vinblastine Sulfate, Dacarbazine, Cyclophosphamide, Etoposide phosphate, prednisone, Radiation Therapy, Fludeoxyglucose F-18, computed tomography, Positron Emission Tomography
- Biological · Drug · Radiation + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 95
- States / cities
- Tucson, Arizona • Duarte, California • New Haven, Connecticut + 72 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 73–96
of 1,297
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma
- Interventions
- Epoetin Alfa, Exercise, Autologous Peripheral Blood Stem Cell Transplantation, Red Blood Cell Transfusion, Thalidomide, Heparin, Low-Molecular-Weight, Platelet Transfusion, Melphalan, Total Therapy II
- Drug · Behavioral · Biological
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- Not listed
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2004
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts
- Interventions
- decitabine, idarubicin, cytarabine
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
- Interventions
- choline magnesium trisalicylate, idarubicin, cytarabine, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Leukemia
- Interventions
- filgrastim, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, mitoxantrone, Asparaginase, prednisone, thioguanine, vincristine, radiation therapy, allopurinol, bactrim
- Biological · Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 78
- States / cities
- Burbank, California • Maywood, Illinois • Chanute, Kansas + 45 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- rituximab, epirubicin hydrochloride
- Biological · Drug
- Lead sponsor
- Fox Chase Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Osteosarcoma
- Interventions
- Cisplatin, Doxorubicin, Methotrexate
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lymphoma
- Interventions
- bevacizumab, filgrastim, pegfilgrastim, bortezomib, cyclophosphamide, doxorubicin hydrochloride, etoposide, ganciclovir, valganciclovir, zidovudine
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Ewing's Sarcoma
- Interventions
- Vincristine, Doxorubicin, Cyclophosphamide, Dexrazoxane, ImmTher
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 3 Years to 60 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Consolidation - CFZ-TD-PACE, Maintenance - CFZ-R(T)-D
- Device · Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Breast Cancer
- Interventions
- Doxorubicin, Cyclophosphamide, Paclitaxel, Bevacizumab
- Drug
- Lead sponsor
- Ian E. Krop, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Hooksett, New Hampshire
- Conditions
- Leukemia
- Interventions
- filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride
- Biological · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 56 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 98
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
- Conditions
- Multiple Myeloma, Plasma Cell Myeloma
- Interventions
- bortezomib, cisplatin, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, etoposide, lenalidomide, melphalan, thalidomide, gene expression analysis, microarray analysis, laboratory biomarker analysis, autologous-autologous tandem hematopoietic stem cell transplantation
- Drug · Genetic · Other + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 21
- States / cities
- Alexandria, Louisiana • Baton Rouge, Louisiana • Detroit, Michigan + 12 more
- Conditions
- Glioma, Pilocytic Astrocytoma, Anaplastic Astrocytoma, Glioblastoma, Mixed Oligoastrocytoma, Mixed Glioma, Oligodendroglioma, Optic Glioma, Astrocytoma
- Interventions
- MRI-guided laser ablation, Doxorubicin, Etoposide, Dynamic contrast-enhanced (DCE) MRI, Dynamic susceptibility contrast (DSC) MRI
- Device · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Sarcoma
- Interventions
- doxorubicin hydrochloride, ifosfamide and mesna, hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Mark Dewhirst
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2009
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- doxorubicin hydrochloride, octreotide acetate
- Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2002
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Carcinoma, Hepatocellular
- Interventions
- Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin, Doxorubicin/Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Orange, California + 11 more
- Conditions
- Sarcoma
- Interventions
- Aranesp (darbepoetin alfa), Neulasta (pegfilgrastim), Adriamycin, Ifosfamide
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2006
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ovarian Cancer, Sarcoma
- Interventions
- cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vincristine sulfate, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery, brachytherapy, intraoperative radiation therapy, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- epirubicin hydrochloride, irinotecan hydrochloride
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Metastatic Urothelial Carcinoma, Transitional Cell Carcinoma, Unresectable Transitional Cell Carcinoma
- Interventions
- Doxorubicin Hydrochloride, Gemcitabine Hydrochloride, Ixazomib Citrate
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Anemia, Leukemia, Neutropenia, Thrombocytopenia
- Interventions
- filgrastim, leridistim, cytarabine, daunorubicin hydrochloride
- Biological · Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 55 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Ovarian Cancer
- Interventions
- carboplatin, doxorubicin hydrochloride
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 120 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Lymphoma
- Interventions
- Fludarabine, Novantrone, Decadron, Rituximab, Interferon, Doxorubicin, Vincristine, Bleomycin, Cyclophosphamide, Etoposide, Cisplatin, Ara-C, Methyl-Prednisolone, Procarbazine, Prednisone
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 76 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2017
- U.S. locations
- 1
- States / cities
- Houston, Texas